Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
May 10, 2024 17:40 ET
|
Tevogen Bio Inc
$50 million in financing advances operational objectives and bolsters a financial path to positive cashflow with minimal dilution.
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
May 09, 2024 16:25 ET
|
Genelux Corporation
Genelux Corporation Reports First Quarter 2024 Financial Results and Provides General Business Updates
HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 09, 2024 16:05 ET
|
HilleVax, Inc.
Topline data from NEST-IN1 Phase 2B clinical study of HIL-214 in infants expected in mid-2024 $272.7 million of cash, cash equivalents and marketable securities as of March 31, 2024 BOSTON, May ...
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results
May 09, 2024 08:30 ET
|
Quoin Pharmaceuticals, Inc.
FDA clearance to recruit teens in both on-going Netherton Syndrome clinical studies U.S. and International patent filed for novel Netherton Syndrome combination product Cash runway extended into...
Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET
|
Phathom Pharmaceuticals
Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report Net revenues of $1.9 million reported for the first full...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:45 ET
|
Virios Therapeutics
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:05 ET
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
May 08, 2024 09:00 ET
|
Turnstone Biologics Corp.
Dr. Sammy Farah, Turnstone's President and CEO, to present at the 2024 Bank of America Securities Health Care Conference in Las Vegas, NV.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
May 08, 2024 06:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present at BofA Securities 2024 Health Care Conference